AI eye in the scope: new tool aims to catch stomach cancer earlier
NCT ID NCT07395570
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an artificial intelligence system (called CADe) can help doctors spot early stomach cancers during endoscopy. About 260 people at high risk for stomach cancer will have two endoscopies: one without the AI and one with it. The goal is to see if the AI reduces the number of cancers that are missed. If it works, this could lead to earlier treatment and better survival.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CADe System (artificial intelligence software for endoscopy)
- What this could lead to
- If successful, this AI tool could help doctors find early stomach cancers more reliably, potentially improving survival rates by catching the disease sooner.
- What could go wrong
- This is a small, early-stage study (260 participants) testing a prototype system. The AI may not work as well in real-world settings or for all types of gastric lesions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 260 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \>=18 * Deemed at high risk of gastric cancer, defined as below: 1. Family history of stomach cancer (1st degree relative) for screening, or 2. Known gastric atrophy/ intestinal metaplasia requiring surveillance, or 3. Suspicious lesion for repeat diagnostic OGD, or 4. History of gastric dysplasia / early gastric cancer with endoscopic resection for surveillance 5. Newly diagnosed early gastric cancer, workup for synchronous cancers Exclusion Criteria: * History of gastrectomy (For any reason, including benign and malignant disease) * Patient who refused to participate * Patients deemed not fit for consent, including minor patients * Pregnancy * Other cases deemed by the examining physician as unsuitable for safe treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric neoplasia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Surgery, Faculty of Medicine, the Chinese University of Hong Kong
Hong Kong, Hong Kong